Want to see EVH full AI Analyst Report?
EVH Stock Chart & Stats
$2.84
<$0.01(0.08%)
At close: 4:00 PM EST
$2.84
<$0.01(0.08%)
Day’s Range― - ―
52-Week Range$2.10 - $10.35
Previous CloseN/A
Volume268.11K
Average Volume (3M)2.36M
Market Cap
$653.52M
Enterprise Value$1.07K
Total Cash (Recent Filing)$166.00M
Total Debt (Recent Filing)$985.42M
Price to Earnings (P/E)―
Beta0.33
Next Earnings
Aug 06, 2026EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.68
Shares Outstanding112,481,064
10 Day Avg. Volume1,807,051
30 Day Avg. Volume2,361,876
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)1.10
Price to Sales (P/S)0.24
P/FCF Ratio96.07
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$5.94Price Target Upside109.31% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering11
EPS Forecast (FY)0.17
Revenue Forecast (FY)$2.50B
Bulls Say, Bears Say
Bulls Say
Platform-scale Contract WinsLarge, multi-year Performance Suite contracts materially increase recurring revenues and deepen client integration. These wins demonstrate scalable cross-sell capability and long-term stickiness with payors, improving revenue visibility and structural growth as launches mature into ongoing fee streams.
Material Deleveraging And Liquidity RunwayA sharply reduced debt load and healthy cash position materially lower refinancing and solvency risk, providing financial flexibility to invest in launches and automation. A longer maturity profile (no maturities until 2029) supports multi-quarter execution without immediate capital markets dependence.
Automation And AI Driving EfficiencyProgress in AI/automation reduces manual review costs and scales clinical workflows, offering durable margin upside as authorization volumes grow. Sustained automation gains can lower unit cost, improve throughput across clients, and support long-term improvement in adjusted EBITDA margins.
Bears Say
Sustained Unprofitability And Weak ROEPersistent large net losses and deeply negative return on equity indicate the business is currently destroying shareholder capital despite revenue gains. Sustained unprofitability undermines internal funding capacity and requires sustained margin improvement to justify ongoing investment and support equity value.
Thin, Volatile Free Cash FlowVery limited and volatile free cash flow constrains the company's ability to self-fund product development, reserves, or client onboarding costs. Reliance on narrow FCF margins makes the company vulnerable to timing swings, increasing probability of external financing if adverse shocks persist.
Exchange Membership Exposure Weighs RevenueHigh sensitivity to exchange enrollment creates structural revenue and reserving uncertainty for specialty services. Large assumed disenrollment and associated servicing/reserve costs can depress margins and complicate forecasting, making specialty revenue growth and profitability dependent on member retention dynamics.
Evolent Health News
EVH FAQ
What was Evolent Health Inc.’s price range in the past 12 months?
Evolent Health Inc. lowest stock price was $2.10 and its highest was $10.35 in the past 12 months.
What is Evolent Health Inc.’s market cap?
Evolent Health Inc.’s market cap is $653.52M.
When is Evolent Health Inc.’s upcoming earnings report date?
Evolent Health Inc.’s upcoming earnings report date is Aug 06, 2026 which is in 18 days.
How were Evolent Health Inc.’s earnings last quarter?
Evolent Health Inc. released its earnings results on May 07, 2026. The company reported -$0.02 earnings per share for the quarter, beating the consensus estimate of -$0.049 by $0.029.
Is Evolent Health Inc. overvalued?
According to Wall Street analysts Evolent Health Inc.’s price is currently Undervalued.
Does Evolent Health Inc. pay dividends?
Evolent Health Inc. does not currently pay dividends.
What is Evolent Health Inc.’s EPS estimate?
Evolent Health Inc.’s EPS estimate is >-0.01.
How many shares outstanding does Evolent Health Inc. have?
Evolent Health Inc. has 112,481,064 shares outstanding.
What happened to Evolent Health Inc.’s price movement after its last earnings report?
Evolent Health Inc. reported an EPS of -$0.02 in its last earnings report, beating expectations of -$0.049. Following the earnings report the stock price went up 11.488%.
Which hedge fund is a major shareholder of Evolent Health Inc.?
Currently, no hedge funds are holding shares in EVH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Evolent Health Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$5.94 (109.31% Upside)
$5.94 (109.31% Upside)
Blogger Sentiment
Bullish
EVH Sentiment 70%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Increased
By 86.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.1%
Last 30 Days ▲ 5.7%
Last 30 Days ▲ 5.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-48.44%
12-Months-Change
Fundamentals
Return on Equity
-77.89%
Trailing 12-Months
Asset Growth
-29.19%
Trailing 12-Months
Company Description
Evolent Health Inc.
Evolent Health, Inc., a prominent healthcare firm, operates through its subsidiary, Evolent Health LLC, to furnish clinical and administrative solutions to both healthcare payers and providers across the United States. Its operations are divided into two principal segments: Evolent Health Services and Clinical Solutions. The Evolent Health Services division delivers an integrated platform encompassing both administrative and clinical functions, specifically designed for health plan management and the oversight of population health. This includes essential financial and administrative support, such as managing health plan operations, risk assessment, robust analytics and reporting, and strategic leadership. A cornerstone of this segment is "Identifi," its proprietary technology, which intelligently aggregates and analyzes data, streamlines care workflows, and actively engages patients, all with the aim of achieving patient-centered and cost-effective population health outcomes. Conversely, the Clinical Solutions segment specializes in offering sophisticated care management services for various stakeholders involved in specialty care delivery. These services are crucial for organizations transitioning from traditional fee-for-service models to value-based care, accommodating their unique stage of development and prevailing market dynamics, particularly in the fields of oncology and cardiology. The overarching objective of this segment is a holistic improvement in the total cost of care. Founded in 2011, Evolent Health, Inc. maintains its corporate headquarters in Arlington, Virginia.
EVH Stock 12 Month Forecast
Average Price Target
$5.94
▲(109.31% Upside)
Technical Analysis
Ownership Overview
2.84% Insiders
13.41% Mutual Funds
0.40% Other Institutional Investors
70.61% Public Companies and
Individual Investors